CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. NTAP status provides supplemental CMS reimbursement above standard hospital payments to support access to innovative therapies like ZEVASKYN.